Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GlaxoSmithKline plc
Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.
Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.
Accelerated Approval Makes Big Splash In 2021 Novel Agents, Despite Crackdown On ‘Dangling’ Cancer Claims
US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.
- Other Names / Subsidiaries
- ABR Development
- Corixa Corporation
- Fountain Acquisition Corporation
- Genelabs Technologies, Inc.
- GlycoVaxyn AG
- Human Genome Sciences, Inc.
- ID Biomedical Corporation
- Okairos AG
- PRAECIS Pharmaceuticals, Inc.
- Reliant Pharmaceuticals
- Sirtris Pharmaceuticals
- Sitari Pharmaceuticals, Inc.
- SmithKline Beecham
- Stiefel Laboratories, Inc.
- Tesaro, Inc.
- ViiV Healthcare